<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188484</url>
  </required_header>
  <id_info>
    <org_study_id>IDIAP Jordi Gol</org_study_id>
    <secondary_id>275/C/2015</secondary_id>
    <nct_id>NCT03188484</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation Research In CATalonia</brief_title>
  <acronym>AFRICAT</acronym>
  <official_title>Stepwise High Risk Individuals Screening for Atrial Fibrillation Using Sequential Clinical-electro-biological Register: the AFRICAT Study (Atrial Fibrillation Research In CATalonia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordi Gol i Gurina Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Institute of Research (VHIR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jordi Gol i Gurina Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AFRICAT study is a prospective, multicenter, population-based study, which aims to create&#xD;
      and apply a sequential screening program for atrial fibrillation (AF) in a high-risk&#xD;
      population by integrating clinical, electrocardiographic and biological information. The&#xD;
      study will be divided into three different phases of generation, validation and application&#xD;
      of a screening program.&#xD;
&#xD;
      In Phase I, from 8,000 individuals aged 65-75 with hypertension and diabetes identified from&#xD;
      primary center registries, 100 will be randomly selected . In these patients, the&#xD;
      investigators will complete clinical assessment, testing of different pulse-handheld ECG&#xD;
      devices (MyDiagnostik, AliveCor and WatchBP) for AF screening, discovery of blood biomarkers&#xD;
      for AF (by aptamer technology and RNA expression), and validation of biological candidates&#xD;
      from the literature and previous results. All patients will receive Holter monitoring with a&#xD;
      wearable device (NuuboTM). In parallel, a predictive risk model for AF will be developed from&#xD;
      historical records from the areas in which the study will be carried out.&#xD;
&#xD;
      This Phase I will be followed by a Phase II-validation phase of 400 patients, selected by the&#xD;
      predictive model previously mentioned, belonging to the top risk quartile. In these patients,&#xD;
      the best biomarkers and devices from phase I will be validated, and patients will be again&#xD;
      monitored with the wearable Holter device.&#xD;
&#xD;
      With the results from this validation analysis, a screening program (Phase III) based in the&#xD;
      combination of clinical predictors, devices to detect AF (handheld-ECG or pulse wave&#xD;
      detectors), blood biomarkers determination and long-term monitoring with wearable Holter.&#xD;
      This program will be applied over the whole population targeted by the AFRICAT study, which&#xD;
      corresponds to 8,000 patients from 65 to 75 years old, whit hypertension and diabetes&#xD;
      mellitus as comorbidities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has been approved by the Ethics Committee of Research Institute IDIAP Jordi Gol&#xD;
      (P15/047/2015) and by Hospital Universitari Vall d'Hebron Clinical Research Ethics Committee&#xD;
      (PR(AG)133-2015). The study will be conducted in compliance with the Declaration of Helsinki.&#xD;
      Registry information was collected from the government-run healthcare provider responsible&#xD;
      for all inpatient care in Catalonia. All participants will receive written information and&#xD;
      thereafter sign informed consent before inclusion, will be selected among the electronic&#xD;
      registers from two different health areas in Catalonia, and will be identified by their&#xD;
      10-digit personal identification number assigned to all citizens in Catalonia.&#xD;
&#xD;
      These patients will be given an appointment in their primary care centre and will receive a&#xD;
      comprehensive assessment consisting of:&#xD;
&#xD;
        -  Clinical characteristics: demographic factors (age, gender, habits); vascular risk&#xD;
           factors (hypertension, diabetes, dyslipidemia), medications, comorbidities (especially&#xD;
           those related to AF such as coronary disease, heart failure), vital signs (blood&#xD;
           pressure, glycaemia, weight and height).&#xD;
&#xD;
        -  Electrocardiographic assessment: three different devices will be tested on each&#xD;
           participant (MyDiasnostik, AliveCor and WatchBP). A conventional ECG will be performed&#xD;
           to be compared with the results from these devices.&#xD;
&#xD;
        -  Blood sample collection: a blood sample of 32 cc divided into two serum tubes (8.5 cc),&#xD;
           two plasma EDTA tubes (6 cc) and one TempusTM RNA tube (3 cc). Samples will be processed&#xD;
           and stored at -20 ºC at the recruiting centre until shipment to Neurovascular Research&#xD;
           Laboratory, where the sample bank will be set up.&#xD;
&#xD;
        -  Holter ECG monitoring: a Nuubo Holter will be given to each patient to be carried for&#xD;
           four weeks. Electrocardiographic devices will be read blindly. The device records,&#xD;
           anonymized and encrypted, will be sent for blinded reading to the Rhythm Disorders Unit&#xD;
           from Hospital Virgen del Rocio in Seville.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Atrial fibrillation (AF) diagnosis</measure>
    <time_frame>Study visit/1 month monitoring</time_frame>
    <description>Absence of discrete P waves together with an irregular, arrhythmic pattern of ventricular activation, more than 30 seconds.</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Arrhythmia Atrial</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A blood sample of 32 cc divided into two serum tubes (8.5 cc), two plasma EDTA tubes (6 cc)&#xD;
      and one TempusTM RNA tube (3 cc). Samples will be processed and stored at -20 ºC at the&#xD;
      recruiting center until shipment to Neurovascular Research Laboratory, where the sample bank&#xD;
      will be set up.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All people included were managed by the Public Health System. Therefore 5,000 participants&#xD;
        aged 65-75 with active diagnoses of hypertension (I10) and diabetes (E10.9 E11.9) will be&#xD;
        selected from the electronic health record of Primary Care. Given that the registered&#xD;
        prevalence of Atrial Fibrillation in this population is was 7.3%, the investigators&#xD;
        estimated that around 2.8% will be newly diagnosed with AF at the first study visit.&#xD;
        Therefore, the investigators estimate that the number of patients in this population who&#xD;
        have undiagnosed AF might be from 140 to 210 patients, taking into account that AF&#xD;
        detection should be improved in the study given the long-term monitoring.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients aged 65-75 with active diagnoses of hypertension (I10) and diabetes (E10.9&#xD;
        E11.9)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence or not accessibility to singular person or its clinical record or/and&#xD;
             difficulty to follow the instructions about how managing the devices or/and no&#xD;
             acceptation of conditions&#xD;
&#xD;
          -  Chronic inflammatory diseases&#xD;
&#xD;
          -  Active Cancer&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  For Phases II-III: previous diagnosis of AF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Montaner Villalonga, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Neurovascular Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J Lluis Clua Espuny, PhD</last_name>
    <phone>(34) 6487439</phone>
    <email>jlclua.ebre.ics@gencat.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alejandro Bustamante Rangel, PhD</last_name>
    <phone>(34) 934-894-029</phone>
    <email>alejandro.bustamante@vhir.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SAP Terres de l'Ebre</name>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Lluis Clúa-Espuny, Md, PhD</last_name>
      <phone>34 977510018</phone>
      <email>jlclua.ebre.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SAP Muntanya</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Angel Muñoz-Pérez, MD, PhD</last_name>
      <phone>34 932075752</phone>
      <email>mamunoz.bcn.ics@gencat.cat</email>
    </contact>
    <contact_backup>
      <last_name>Alejandro Bustamante, MD, PhD</last_name>
      <phone>34 934894029</phone>
      <phone_ext>4940</phone_ext>
      <email>alejandro.bustamante@vhir.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jordi Gol i Gurina Foundation</investigator_affiliation>
    <investigator_full_name>Josep Lluís Clua Espuny</investigator_full_name>
    <investigator_title>PhD Medicine and Surgery</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Electrocardiography</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Risk Assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

